<DOC>
	<DOCNO>NCT00216671</DOCNO>
	<brief_summary>The primary objective randomize trial investigate whether early initiation treatment Risperdal Consta acute episode inferior routine approach ( oral treatment 12 week follow treatment Risperdal Consta ) . .</brief_summary>
	<brief_title>Long-acting Injectable Risperidone Patients With Schizophrenia After Acute Episode</brief_title>
	<detailed_description>Although many schizophrenia patient currently take oral antipsychotic medication , estimate 75 % difficulty adhere daily oral regiment . Long-acting injectable formulation may eliminate need daily medication enhance patient compliance treatment regimen . Traditionally , patient experience episode schizophrenia first treat oral medication stabilize , injectable long-acting formulation give . This open , multicenter , randomize Phase IV trial patient acute episode schizophrenia . Patients trial 6 month . One treatment group receive injection start baseline ( early initiation ) ; group start treatment usual baseline begin injection Week 12 ( late initiation ) . Assessment effectiveness include Positive And Negative Syndrome Scale ( PANSS ) , order measure symptoms schizophrenia ; Clinical Global Impression - Severity ( CGI-S ) , measure overall severity illness ; Global Assessment Functioning ( GAF ) , assess overall psychological , social , occupational functioning ; Quality Life Questionnaire SF-12 , measure overall health status . Safety evaluation include Extrapyramidal Symptoms Rating Scale ( ESRS ) , incidence adverse event throughout study , vital sign ( pulse , blood pressure ) . The study hypothesis early initiation long-acting risperidone injection inferior late initiation measure change PANSS total score baseline endpoint ( 6 month ) . Risperidone , long-acting formulation intramuscular injection ( 25 50 mg ( maximum ) ) , give every 14 day 6 month , start baseline Month 3 . Treatment usual 3 month late initiation group</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Diagnosis schizophrenia criterion Diagnostic Statistical Manual Mental Diseases , Fourth Edition ( DSMIV ) acute episode schizophrenia within 2 week study entry subject currently treat treated oral antipsychotic shortacting injectable antipsychotic ( zuclopenthixol acutard allow ) dose exceed register dose Positive And Negative Syndrome Scale ( PANSS ) score &gt; =80 Clinical Global Impression Severity ( CGIS ) score &gt; =5 DSMIV axis I diagnosis schizophrenia know hypersensitivity lack response risperidone pregnant nursing female , without adequate contraception alcohol drug abuse dependence diagnose last month prior entry ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>intramuscular injection</keyword>
	<keyword>antipsychotic agent</keyword>
	<keyword>long-acting risperidone</keyword>
</DOC>